AMAntonio Mura

Antonio Mura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Mura has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Gianfranco Sinagra

    Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, 34149 Trieste, Italy

    2 shared publications
  • Mateusz Tomczyk

    School of Cardiovascular and Metabolic Medicine and Sciences and BHF Centre for Research Excellence and Medical Research Council/British Heart Foundation Centre of Research Excellence in Advanced Cardiac Therapies, King’s College London, London, United Kingdom (M.T., I.K., G.L., L.V., J.H., C.K.W., A.C.).

    2 shared publications
  • Mauro Giacca

    King's College London

    2 shared publications
  • Angelica Cadoni

    School of Cardiovascular and Metabolic Medicine and Sciences and BHF Centre for Research Excellence and Medical Research Council/British Heart Foundation Centre of Research Excellence in Advanced Cardiac Therapies, King’s College London, London, United Kingdom (M.T., I.K., G.L., L.V., J.H., C.K.W., A.C.).

    1 shared publication
  • Antonella Falcione

    Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34139 Trieste, Italy

    1 shared publication
  • Antonio Cannatà

    School of Cardiovascular Medicine and Sciences, King's College London , London

    1 shared publication

Latest Publications

  • Chordin-Like 1 mRNA Therapy for Acute Myocardial Infarction

    by Mateusz Tomczyk, Izabela Kraszewska, Gang Li, Matthew John Hayes, Luca Venditti, Josef Huntington, Chun Kit Wong, Angelica Cadoni, Francesca Bortolotti, Antonio Mura, et al.


  • Cardioprotective factors against myocardial infarction selected in vivo from an AAV secretome library

    by Giulia Ruozi, Francesca Bortolotti, Antonio Mura, Mateusz Tomczyk, Antonella Falcione, Valentina Martinelli, Simone Vodret, Luca Braga, Matteo Dal Ferro, Antonio Cannatà, et al.

    Therapies for patients with myocardial infarction and heart failure are urgently needed, in light of the breadth of these conditions and lack of curative treatments. To systematically identify previously unidentified cardioactive biologicals in an unbiased manner in vivo, we developed cardiac FunSel, a method for the systematic, functional selection of effective factors using a library of 1198 barcoded adeno-associated virus (AAV) vectors encoding for the mouse secretome. By pooled vector injection into the heart, this library was screened to functionally select for factors that confer cardioprotection against myocardial infarction. After two rounds of iterative selection in mice, cardiac FunSel identified three proteins [chordin-like 1 (Chrdl1), family with sequence similarity 3 member C (Fam3c), and Fam3b] that preserve cardiomyocyte viability, sustain cardiac function, and prevent pathological remodeling. In particular, Chrdl1 exerted its protective activity by binding and inhibiting extracellular bone morphogenetic protein 4 (BMP4), which resulted in protection against cardiomyocyte death and induction of autophagy in cardiomyocytes after myocardial infarction. Chrdl1 also inhibited fibrosis and maladaptive cardiac remodeling by binding transforming growth factor–β (TGF-β) and preventing cardiac fibroblast differentiation into myofibroblasts. Production of secreted and circulating Chrdl1, Fam3c, and Fam3b from the liver also protected the heart from myocardial infarction, thus supporting the use of the three proteins as recombinant factors. Together, these findings disclose a powerful method for the in vivo, unbiased selection of tissue-protective factors and describe potential cardiac therapeutics.